Antidepressant prophylaxis for poststroke depression: a meta-analysis.
Given the high incidence of poststroke depression, its serious sequelae, and inherent problems with diagnosis, prophylactic use of antidepressants may be a viable management strategy in patients experiencing stroke. The purpose of this study was to assess the prophylactic effects of antidepressants in nondepressed patients with stroke. A meta-analysis of randomized placebo-controlled trials evaluating the prophylactic effects of antidepressants in nondepressed patients with stroke was conducted. Literature searches in MEDLINE, PubMed, CINAHL, PsycINFO, EMBASE, Cochrane library, and CNKI from 1950 to August 2006 were used to identify the relevant studies. Outcome measures included the occurrence rate of newly developed poststroke depression cases and severity of depressive symptoms as indicated by mean depression rating scale scores. The effect size was presented as rate difference or weighted mean difference. From 10 randomized clinical trials, a total of 703 nondepressed patients after stroke were identified. The pooled occurrence rate of newly developed poststroke depression cases in the intervention and control groups were 12.54 (41/327) and 29.17% (91/312), respectively (pooled rate difference=-0.17, 95% confidence interval: -0.26 to -0.08). Prophylactic effects of antidepressants were not related to duration of use {coefficient of Pearson's correlation [gamma]=0.57, P=0.11}. In conclusion, antidepressant prophylaxis is associated with a significant reduction in the occurrence rate of newly developed poststroke depression, suggesting antidepressants may be considered along with other vascular preventive strategies in the management of stroke patients.
Chen
Yan
Y
Pharmacoepidemiology and Pharmacoeconomics, Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0004, USA. yance@email.uc.edu
Patel
Nick C
NC
Guo
Jeff J
JJ
Zhan
Siyan
S
D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002544:Cerebral Infarction / Q000523:psychology*; D003866:Depressive Disorder / Q000175:diagnosis / Q000517:prevention & control* / Q000523:psychology; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D000928:Antidepressive Agents